Showing 4661-4670 of 5771 results for "".
- DORC Launches New Range of EVA EquiPhaco Needles and Sleeveshttps://modernod.com/news/dorc-launches-new-range-of-eva-equiphaco-needles-and-sleeves/2477940/DORC announced the launch of a new range of EVA EquiPhaco needles and sleeves, which are designed to deliver superior ultrasound efficiency, improved anterior chamber stability, and easier sleeve positioning. T
- US Sues Regeneron Over Alleged Kickbacks for Eyleahttps://modernod.com/news/us-sues-regeneron-over-alleged-kickbacks-for-eylea/2477932/The US Attorney for the District of Massachusetts announced on Wednesday that the government filed a civil complaint against Regeneron Pharmaceuticals, alleging that the drugmaker paid $35 million in kickbacks for Eylea (aflibercept), using a foundation as a conduit to cover co-pays for the VEGF
- Sight Sciences Names New Chief Operating Officer and General Counselhttps://modernod.com/news/sight-sciences-names-new-chief-operating-officer-and-general-counsel/2477930/Sight Sciences announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. “We are excited to be able to add leaders with the outstanding track records of Sam and Jeremy as Sight Sciences continu
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- Johnson & Johnson Vision Donates $320K to Support Practitioners and Schools of Optometry Impacted by COVID-19https://modernod.com/news/johnson-johnson-vision-donates-320k-to-support-practitioners-and-schools-of-optometry-impacted-by-covid-19/2477924/As part of ongoing initiatives to help support eye care in the wake of COVID-19, Johnson & Johnson Vision announced donations to Optometry Cares, the charitable foundation of The American Optometric Association (AOA) Foundation and the American Academy of Optometry Foundation (AAOF). A
- Visual Clinic’s ‘Safe Visits’ Aims to Help Eye Care Clinics Comply with New Post-COVID-19 Protocolshttps://modernod.com/news/visual-clinics-safe-visits-aims-to-help-eye-care-clinics-comply-with-new-post-covid-19-protocols/2477921/Visual Clinic announced the launch of its Safe Visits application. The software module provides ophthalmology and optometry practices with a streamlined care process that safely and efficiently guides patients and staff through appointments in the post-COVID-19 environment, according to a company
- Aurinia Completes Patient Enrollment In Phase 2/3 Trial of Voclosporin for the Treatment of Dry Eyehttps://modernod.com/news/aurinia-completes-patient-enrollment-in-phase-2-3-trial-of-voclosporin-for-the-treatment-of-dry-eye/2477914/Aurinia Pharmaceuticals announced it has completed enrollment for the phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Voclosporin’s proven mechanism of action as a novel calcineurin inhibitor gives us
- Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen for the Treatment of Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reinitiates-patient-enrollment-in-clinical-study-of-opregen-for-the-treatment-of-dry-amd-with-geographic-atrophy/2477911/Lineage Cell Therapeutics announced that it has restarted patient enrollment in a phase 1/2a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD),
- Santen and Orbis International Join Forces to Expand Access to Training for Eye Care Professionals Through Telemedicine Platformhttps://modernod.com/news/santen-and-orbis-international-join-forces-to-expand-access-to-training-for-eye-care-professionals-through-telemedicine-platform/2477910/Santen Pharmaceutical and Orbis International announced a partnership to develop a suite of digital training tools that will continue to help eye care professionals around the world build their skills. Through the 3-year, global partnership, Orbis and Santen will create online courses, live surgi
- ImprimisRx’s Patented Klarity-C 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometristshttps://modernod.com/news/imprimisrxs-patented-klarity-c-0-1-cyclosporine-preservative-free-formulation-may-now-be-prescribed-by-floridas-2000-optometrists/2477907/ImprimisRx announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. Klarity-C w